bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Morgan Stanley Healthcare Conference to be held September 9 - 11, 2013 at the Grand Hyatt Hotel, New York, NY. Nick Leschly, Chief bluebird, will provide an overview of the company at the Morgan Stanley Conference on Wednesday, September 11, 2013 at 8:00 AM (ET).
To access a simultaneous webcast of Mr. Leschly's overview via the internet, log on to the "Calendar of Events" section on the Investor and Media page of the bluebird bio's website at
. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.
A replay of the webcasts will be available on bluebird bio's website for ninety days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Calendar of Events" section of the Investor and Media page of the bluebird bio's website at
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, recently initiated a phase 2/3 study for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in a phase 1/2 study in France for the treatment of beta-thalassemia major and severe sickle cell disease. A second phase 1/2 study with LentiGlobin has been initiated in the United States for the treatment of beta-thalassemia major.
bluebird bio also has an early-stage chimeric antigen receptor-modified T cell (CAR-T) program for oncology in partnership with Celgene Corporation. bluebird bio has operations in Cambridge, Massachusetts, San Francisco, California and Paris, France. For more information, please visit
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of our clinical trials.
Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaboration with Celgene will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the final prospectus related to our initial public offering filed with the Securities and Exchange Commission pursuant to Rule 424(b) of the Securities Act, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.
All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.